{
    "hands_on_practices": [
        {
            "introduction": "The journey of managing pediatric nephrotic syndrome begins with a swift and accurate diagnosis. This initial step hinges on the precise interpretation of core clinical and laboratory data. This exercise  provides a foundational practice in applying the formal quantitative criteria for nephrotic syndrome, focusing on the calculation of the urine protein-to-creatinine ratio ($UPCR$) from a spot sample. Mastering this skill is essential, as it transforms raw laboratory values into a definitive diagnosis, paving the way for timely and appropriate therapeutic intervention.",
            "id": "5188483",
            "problem": "A pediatric patient presents with generalized edema, and laboratory values show urine protein concentration $300$ $\\mathrm{mg/dL}$, urine creatinine concentration $100$ $\\mathrm{mg/dL}$, and serum albumin $2.2$ $\\mathrm{g/dL}$. In pediatric nephrotic syndrome—commonly caused by Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)—the defining features include nephrotic-range proteinuria, hypoalbuminemia, and edema. The urine protein-to-creatinine ratio (UPCR) is widely used as a proxy for $24$-hour protein excretion because urine creatinine excretion per unit time is relatively stable for a given muscle mass and the ratio normalizes for urine concentration. Use the fundamental definitions that nephrotic-range proteinuria in children corresponds to a urine protein-to-creatinine ratio $R \\ge 2 \\, \\mathrm{mg/mg}$, hypoalbuminemia corresponds to serum albumin $\\le 2.5 \\, \\mathrm{g/dL}$, and clinical edema indicates extravascular fluid accumulation driven by reduced plasma oncotic pressure.\n\nCompute the urine protein-to-creatinine ratio $R$ defined by $R=\\frac{\\text{urine protein}}{\\text{urine creatinine}}$ and then define the indicator variable $I$ such that $I=1$ if and only if all three nephrotic syndrome criteria are met (nephrotic-range proteinuria, hypoalbuminemia, and edema), and $I=0$ otherwise. Express $R$ in $\\mathrm{mg/mg}$. Report your final answer as a row matrix $\\begin{pmatrix} R & I \\end{pmatrix}$ using the LaTeX $\\texttt{pmatrix}$ environment. Provide exact values; no rounding is required.",
            "solution": "The problem requires the validation of a clinical scenario against the formal diagnostic criteria for pediatric nephrotic syndrome. The task is to compute two values: the urine protein-to-creatinine ratio, denoted by $R$, and an indicator variable, $I$, which signals whether the full set of criteria for nephrotic syndrome is met.\n\nFirst, we address the calculation of the urine protein-to-creatinine ratio, $R$. The problem defines this ratio as $R = \\frac{\\text{urine protein}}{\\text{urine creatinine}}$. The provided laboratory values are a urine protein concentration of $300 \\, \\mathrm{mg/dL}$ and a urine creatinine concentration of $100 \\, \\mathrm{mg/dL}$. When computing the ratio of these two concentrations measured from the same spot urine sample, the volume unit ($\\mathrm{dL}$) cancels out, yielding a dimensionless ratio of mass to mass. The problem specifies the units for $R$ as $\\mathrm{mg/mg}$, which is consistent with this calculation.\n\nLet $P_u$ be the urine protein concentration and $C_u$ be the urine creatinine concentration.\nGiven:\n$$ P_u = 300 \\, \\mathrm{mg/dL} $$\n$$ C_u = 100 \\, \\mathrm{mg/dL} $$\nThe ratio $R$ is calculated as:\n$$ R = \\frac{P_u}{C_u} = \\frac{300 \\, \\mathrm{mg/dL}}{100 \\, \\mathrm{mg/dL}} = 3 $$\nThe resulting value for $R$ is $3$, with the implicit units being $\\mathrm{mg}$ of protein per $\\mathrm{mg}$ of creatinine.\n\nNext, we must determine the value of the indicator variable $I$. The problem states that $I=1$ if and only if all three specified criteria for nephrotic syndrome are met, and $I=0$ otherwise. We must evaluate each criterion systematically.\n\n1.  **Nephrotic-range proteinuria**: The criterion is defined as a urine protein-to-creatinine ratio $R \\ge 2 \\, \\mathrm{mg/mg}$. Our calculated value is $R=3$. Since $3 \\ge 2$, this criterion is satisfied.\n\n2.  **Hypoalbuminemia**: The criterion is defined as a serum albumin level $\\le 2.5 \\, \\mathrm{g/dL}$. The patient's given serum albumin is $2.2 \\, \\mathrm{g/dL}$. Since $2.2 \\le 2.5$, this criterion is satisfied.\n\n3.  **Edema**: The problem statement explicitly notes that the \"pediatric patient presents with generalized edema\". Therefore, this clinical criterion is satisfied by observation as given in the problem's setup.\n\nSince all three criteria—nephrotic-range proteinuria, hypoalbuminemia, and edema—are met, the conditions for setting the indicator variable $I$ to $1$ are fulfilled.\nTherefore, $I=1$.\n\nFinally, the problem asks for the final answer to be presented as a row matrix $\\begin{pmatrix} R & I \\end{pmatrix}$. Substituting the computed values for $R$ and $I$, we obtain the matrix $\\begin{pmatrix} 3 & 1 \\end{pmatrix}$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n3 & 1\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "Following a diagnosis of steroid-sensitive nephrotic syndrome, typically caused by Minimal Change Disease (MCD), initiating a standardized corticosteroid regimen is the critical next step. This hands-on problem  translates clinical guidelines into practice by requiring the calculation of a complete, weight-based prednisone protocol, from induction to a multi-step taper. By also incorporating the definition of remission based on home monitoring, this exercise develops the essential skill of planning and quantifying a full treatment course, which is vital for ensuring therapeutic efficacy while managing cumulative drug exposure.",
            "id": "5188385",
            "problem": "A $6$-year-old child weighing $20\\,\\mathrm{kg}$ presents with pediatric nephrotic syndrome, with clinical features and laboratory evaluation most consistent with steroid-sensitive minimal change disease (MCD). Standard induction therapy is prednisone $2\\,\\mathrm{mg/kg/day}$ administered once daily for $6$ weeks, followed by an alternate-day taper as follows: $1.5\\,\\mathrm{mg/kg}$ on alternate days for $2$ weeks, then $1.0\\,\\mathrm{mg/kg}$ on alternate days for $2$ weeks, then $0.5\\,\\mathrm{mg/kg}$ on alternate days for $2$ weeks, after which prednisone is stopped. A maximum single prednisone dose cap of $60\\,\\mathrm{mg/day}$ applies at all times. The family performs daily first-morning urine dipstick testing at home. Complete remission is defined as the earliest calendar day on which there have been $3$ consecutive days with urine dipstick protein reported as negative or trace. The first negative dipstick occurs on day $9$ of therapy.\n\nUsing only core definitions (milligram-per-kilogram dosing, alternate-day scheduling, maximum single-dose capping, and the stated remission criterion), and assuming perfect adherence with day $1$ defined as the first day of dosing:\n\n- Compute the earliest calendar day on which complete remission is achieved.\n- Compute the cumulative prednisone dose administered up to and including that remission day.\n- Compute the total cumulative prednisone dose administered over the entire described course (induction plus taper).\n\nExpress all doses in $\\mathrm{mg}$. Round any numerical answers to four significant figures.",
            "solution": "This multi-part problem requires calculating key parameters of a standard prednisone course for pediatric nephrotic syndrome. We will address each part systematically.\n\n### Part 1: Earliest Calendar Day of Complete Remission\n\nThe problem defines complete remission as \"the earliest calendar day on which there have been $3$ consecutive days with urine dipstick protein reported as negative or trace.\"\n- We are given that the first negative dipstick occurs on day $9$.\n- For remission to be achieved, this must be the first of three consecutive negative results.\n- The sequence of negative dipstick days must be Day 9, Day 10, and Day 11.\n- Remission is formally achieved on the third day of this sequence.\nTherefore, the earliest calendar day of complete remission is **Day 11**.\n\n### Part 2: Cumulative Prednisone Dose at Remission\n\nThe patient is in the induction phase of therapy up to day 11.\n- The induction dose rate is $2\\,\\mathrm{mg/kg/day}$.\n- The patient's weight is $20\\,\\mathrm{kg}$.\n- The daily dose is calculated as: $D_{daily} = 2\\,\\mathrm{mg/kg/day} \\times 20\\,\\mathrm{kg} = 40\\,\\mathrm{mg/day}$.\n- This dose is less than the maximum single dose cap of $60\\,\\mathrm{mg/day}$, so the calculated dose applies.\n- The cumulative dose up to and including day 11 is the daily dose multiplied by the number of days.\n$$ C_{remission} = 11\\,\\text{days} \\times 40\\,\\mathrm{mg/day} = 440\\,\\mathrm{mg} $$\nThe cumulative dose at remission is **$440\\,\\mathrm{mg}$**.\n\n### Part 3: Total Cumulative Prednisone Dose Over the Entire Course\n\nWe calculate the total dose by summing the doses from each phase of the protocol.\n\n1.  **Induction Phase:**\n    - Duration: $6\\,\\text{weeks} = 6 \\times 7 = 42\\,\\text{days}$.\n    - Daily Dose: $40\\,\\mathrm{mg/day}$.\n    - Induction Dose: $42\\,\\text{days} \\times 40\\,\\mathrm{mg/day} = 1680\\,\\mathrm{mg}$.\n\n2.  **Taper Phase 1:**\n    - Dose Rate: $1.5\\,\\mathrm{mg/kg}$ on alternate days.\n    - Single Dose: $1.5\\,\\mathrm{mg/kg} \\times 20\\,\\mathrm{kg} = 30\\,\\mathrm{mg}$.\n    - Duration: $2\\,\\text{weeks} = 14\\,\\text{days}$.\n    - Number of Doses (alternate days): $14 / 2 = 7$ doses.\n    - Taper 1 Dose: $7\\,\\text{doses} \\times 30\\,\\mathrm{mg/dose} = 210\\,\\mathrm{mg}$.\n\n3.  **Taper Phase 2:**\n    - Dose Rate: $1.0\\,\\mathrm{mg/kg}$ on alternate days.\n    - Single Dose: $1.0\\,\\mathrm{mg/kg} \\times 20\\,\\mathrm{kg} = 20\\,\\mathrm{mg}$.\n    - Duration: $2\\,\\text{weeks} = 14\\,\\text{days}$.\n    - Number of Doses: $7$ doses.\n    - Taper 2 Dose: $7\\,\\text{doses} \\times 20\\,\\mathrm{mg/dose} = 140\\,\\mathrm{mg}$.\n\n4.  **Taper Phase 3:**\n    - Dose Rate: $0.5\\,\\mathrm{mg/kg}$ on alternate days.\n    - Single Dose: $0.5\\,\\mathrm{mg/kg} \\times 20\\,\\mathrm{kg} = 10\\,\\mathrm{mg}$.\n    - Duration: $2\\,\\text{weeks} = 14\\,\\text{days}$.\n    - Number of Doses: $7$ doses.\n    - Taper 3 Dose: $7\\,\\text{doses} \\times 10\\,\\mathrm{mg/dose} = 70\\,\\mathrm{mg}$.\n\n5.  **Total Cumulative Dose:**\n    $$ C_{total} = C_{induction} + C_{taper1} + C_{taper2} + C_{taper3} $$\n    $$ C_{total} = 1680 + 210 + 140 + 70 = 2100\\,\\mathrm{mg} $$\nThe total cumulative dose is **$2100\\,\\mathrm{mg}$**.\n\n### Final Answer Formatting\n\nThe problem requests answers rounded to four significant figures.\n- Day of remission: $11$ becomes $11.00$.\n- Cumulative dose at remission: $440$ becomes $440.0\\,\\mathrm{mg}$.\n- Total cumulative dose: $2100$ becomes $2.100 \\times 10^3\\,\\mathrm{mg}$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n11.00 & 440.0 & 2.100 \\times 10^3\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "While most children with nephrotic syndrome respond well to steroids, a clinician must be adept at recognizing atypical features that suggest a more complex diagnosis like Focal Segmental Glomerulosclerosis (FSGS). This advanced practice problem  presents two contrasting clinical vignettes—one of classic, steroid-sensitive MCD and one of steroid-resistant FSGS—to sharpen your differential diagnostic skills. Successfully navigating this exercise requires integrating clinical presentation, laboratory results, response to therapy, and histopathological findings to determine the correct diagnosis and formulate distinct, evidence-based management plans for each patient.",
            "id": "5188636",
            "problem": "A child aged $4$ years presents with periorbital edema, abdominal distension, and frothy urine. The urine protein-to-creatinine ratio is $4.8\\,\\mathrm{mg/mg}$, serum albumin is $1.9\\,\\mathrm{g/dL}$, total cholesterol is $290\\,\\mathrm{mg/dL}$, serum creatinine is $0.3\\,\\mathrm{mg/dL}$, and complement component $3$ is within the reference range. There is no macroscopic hematuria and blood pressure is normal for age. The child is treated with oral prednisone at $60\\,\\mathrm{mg/m^2/day}$ and achieves complete remission by day $7$ (urine protein-to-creatinine ratio $<0.2\\,\\mathrm{mg/mg}$). Light microscopy (LM) of the glomeruli performed for research purposes shows no structural abnormalities, and immunofluorescence is negative for immunoglobulin and complement deposition.\n\nAn adolescent aged $15$ years presents with progressive leg edema, elevated blood pressure, and microscopic hematuria. The urine protein-to-creatinine ratio is $8.2\\,\\mathrm{mg/mg}$, serum albumin is $2.1\\,\\mathrm{g/dL}$, serum creatinine is $0.8\\,\\mathrm{mg/dL}$, and complement component $3$ is within the reference range. After $12$ weeks of high-dose oral prednisone at $60\\,\\mathrm{mg/m^2/day}$, there is no remission. Kidney biopsy shows segmental sclerosis involving a subset of glomerular tufts with adhesion to Bowman’s capsule on LM, and immunofluorescence is negative for granular immune complex deposition.\n\nUsing the fundamental definition of nephrotic syndrome as heavy proteinuria with resultant hypoalbuminemia leading to decreased plasma oncotic pressure $\\pi_{c}$ and edema by Starling’s principle of transcapillary fluid flux $J_{v} = K_{f}\\big[(P_{c}-P_{i}) - \\sigma(\\pi_{c}-\\pi_{i})\\big]$, and the structure-function relationship of the glomerular filtration barrier (fenestrated endothelium, glomerular basement membrane, and podocyte slit diaphragm), infer the most consistent diagnoses for each patient, the expected electron microscopy (EM) findings, and the most appropriate immediate management strategy to reduce proteinuria and progression risk.\n\nWhich option best integrates these inferences?\n\nA. The $4$-year-old has Minimal Change Disease (MCD); EM shows diffuse podocyte foot process effacement without immune deposits; continue corticosteroids with gradual taper and supportive care. The $15$-year-old has Focal Segmental Glomerulosclerosis (FSGS); EM shows podocyte effacement with areas of segmental scarring; initiate Renin-Angiotensin-Aldosterone System (RAAS) blockade with an Angiotensin-Converting Enzyme (ACE) inhibitor and consider a Calcineurin Inhibitor (CNI) if nephrotic-range proteinuria persists, with close monitoring for progression to chronic kidney disease.\n\nB. The $4$-year-old has Membranous Nephropathy; EM shows subepithelial immune complex deposits; initiate plasma exchange. The $15$-year-old has MCD; EM is normal; escalate corticosteroids indefinitely.\n\nC. The $4$-year-old has FSGS due to apolipoprotein L1 (APOL1)-associated risk; EM shows segmental sclerosis and hyalinosis; initiate alkylating therapy with cyclophosphamide. The $15$-year-old has MCD; EM shows mesangial immunoglobulin A deposition; continue observation without RAAS blockade.\n\nD. The $4$-year-old has MCD; EM shows mesangial hypercellularity with subendothelial deposits; first-line treatment is mycophenolate mofetil. The $15$-year-old has FSGS; EM shows subendothelial immune complex deposits and low complement; treat with prolonged high-dose steroids alone despite resistance.",
            "solution": "The problem statement will first be validated for scientific soundness, consistency, and completeness before a solution is attempted.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n**Patient 1:**\n- Age: $4$ years\n- Clinical signs: periorbital edema, abdominal distension, frothy urine\n- Laboratory findings:\n    - Urine protein-to-creatinine ratio: $4.8\\,\\mathrm{mg/mg}$\n    - Serum albumin: $1.9\\,\\mathrm{g/dL}$\n    - Total cholesterol: $290\\,\\mathrm{mg/dL}$\n    - Serum creatinine: $0.3\\,\\mathrm{mg/dL}$\n    - Complement component $3$ (C3): within the reference range\n- Physical examination:\n    - No macroscopic hematuria\n    - Blood pressure: normal for age\n- Treatment and response:\n    - Treatment: oral prednisone at $60\\,\\mathrm{mg/m^2/day}$\n    - Response: complete remission by day $7$ (urine protein-to-creatinine ratio $<0.2\\,\\mathrm{mg/mg}$)\n- Histopathology:\n    - Light microscopy (LM): no structural abnormalities\n    - Immunofluorescence (IF): negative for immunoglobulin and complement deposition\n\n**Patient 2:**\n- Age: $15$ years\n- Clinical signs: progressive leg edema, elevated blood pressure, microscopic hematuria\n- Laboratory findings:\n    - Urine protein-to-creatinine ratio: $8.2\\,\\mathrm{mg/mg}$\n    - Serum albumin: $2.1\\,\\mathrm{g/dL}$\n    - Serum creatinine: $0.8\\,\\mathrm{mg/dL}$\n    - Complement component $3$ (C3): within the reference range\n- Treatment and response:\n    - Treatment: high-dose oral prednisone at $60\\,\\mathrm{mg/m^2/day}$ for $12$ weeks\n    - Response: no remission\n- Histopathology:\n    - Light microscopy (LM): segmental sclerosis involving a subset of glomerular tufts with adhesion to Bowman’s capsule\n    - Immunofluorescence (IF): negative for granular immune complex deposition\n\n**Guiding Principles:**\n- Definition of nephrotic syndrome: heavy proteinuria, hypoalbuminemia, decreased plasma oncotic pressure ($\\pi_{c}$), and edema.\n- Starling’s principle of transcapillary fluid flux: $J_{v} = K_{f}\\big[(P_{c}-P_{i}) - \\sigma(\\pi_{c}-\\pi_{i})\\big]$.\n- Structure-function of the glomerular filtration barrier (GFB): fenestrated endothelium, glomerular basement membrane (GBM), and podocyte slit diaphragm.\n\n**Task:**\n- Infer the most consistent diagnoses for each patient.\n- Infer the expected electron microscopy (EM) findings for each patient.\n- Infer the most appropriate immediate management strategy for each patient.\n- Select the option that best integrates these inferences.\n\n**Step 2: Validate Using Extracted Givens**\n\n1.  **Scientifically Grounded:** The problem describes two classic clinical scenarios in pediatric nephrology. The laboratory values presented (e.g., urine protein/creatinine ratio $> 2.0\\,\\mathrm{mg/mg}$, serum albumin $< 3.0\\,\\mathrm{g/dL}$) are definitive for nephrotic syndrome. The reference to Starling's principle and GFB anatomy is fundamentally correct and relevant. The described clinical courses and biopsy findings are characteristic of distinct glomerular diseases. The problem is scientifically sound.\n2.  **Well-Posed:** The problem provides sufficient, consistent clinical and pathological data to allow for a differential diagnosis and inference of expected findings and management, as requested. A unique, logical conclusion can be derived.\n3.  **Objective:** The presentation is based on objective clinical data and established pathophysiological principles. The language is precise and unbiased.\n4.  **Completeness and Consistency:** The data for each patient are internally consistent. For Patient 1, a young age, rapid steroid response, and normal LM/negative IF form a classic triad for Minimal Change Disease. For Patient 2, older age, steroid resistance, hypertension, and segmental sclerosis on LM are classic for Focal Segmental Glomerulosclerosis. The normal C3 levels are consistent with these diagnoses. The problem is both complete and consistent.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is valid. It is scientifically sound, well-posed, and internally consistent. The solution process can proceed.\n\n### Solution Derivation\n\nThe analysis will proceed by applying the provided principles to each patient's case to infer the diagnosis, expected ultrastructural (EM) findings, and appropriate management.\n\n**Patient 1 (4-year-old child):**\n\n1.  **Diagnosis:** The patient's presentation fulfills the criteria for nephrotic syndrome as defined: heavy proteinuria ($4.8\\,\\mathrm{mg/mg}$ protein/creatinine ratio), hypoalbuminemia ($1.9\\,\\mathrm{g/dL}$), and edema. As per Starling's principle, the severe hypoalbuminemia lowers plasma oncotic pressure ($\\pi_{c}$), which reduces the force opposing capillary hydrostatic pressure ($P_c$) and leads to massive fluid flux ($J_v$) into the interstitial space. The key diagnostic feature is the rapid and complete remission achieved with oral prednisone. In a child of this age, this clinical response is highly specific (> $90\\%$) for **Minimal Change Disease (MCD)**. The provided biopsy results—normal glomeruli on light microscopy and negative immunofluorescence—are the definitive histopathological findings for MCD.\n\n2.  **Electron Microscopy (EM) Findings:** The GFB's integrity depends on the podocyte foot processes and the slit diaphragms between them. In MCD, the primary defect is a podocytopathy, leading to a functional loss of the charge- and size-selective barrier. While invisible on LM, this defect is revealed by EM as **diffuse and widespread effacement (fusion) of the podocyte foot processes**. There are no electron-dense immune deposits, consistent with the negative IF findings.\n\n3.  **Management:** The initial, successful treatment with high-dose prednisone was appropriate. Having achieved complete remission, the standard of care is to **continue corticosteroids on a tapering schedule** over several months. This is crucial to maintain remission and reduce the risk of relapse, which is common in MCD. Supportive care, including dietary salt restriction and monitoring for complications, is also integral.\n\n**Patient 2 (15-year-old adolescent):**\n\n1.  **Diagnosis:** This patient also presents with nephrotic syndrome (proteinuria $8.2\\,\\mathrm{mg/mg}$, albumin $2.1\\,\\mathrm{g/dL}$, edema). However, several features point to a different, more aggressive pathology: older age of onset, presence of hypertension and microscopic hematuria, and most critically, **steroid resistance** (failure to remit after $12$ weeks of high-dose prednisone). The kidney biopsy provides the definitive diagnosis: LM shows scarring in segments of some glomeruli (\"focal segmental\"), along with adhesions to Bowman's capsule (synechiae). This is the pathognomonic lesion of **Focal Segmental Glomerulosclerosis (FSGS)**. The negative IF indicates a primary (idiopathic or genetic) form, as opposed to a secondary, immune-mediated cause.\n\n2.  **Electron Microscopy (EM) Findings:** FSGS is also a podocytopathy. Therefore, EM will show **podocyte foot process effacement**, similar to MCD, which can be diffuse even in glomeruli that appear normal on LM. In addition, within the sclerotic segments identified on LM, EM will reveal the ultrastructural details of the scarring process, such as collapse of the glomerular capillary tuft, accumulation of extracellular matrix, and detachment of podocytes from a denuded GBM.\n\n3.  **Management:** This patient has steroid-resistant nephrotic syndrome due to FSGS, a condition with a high risk of progression to chronic kidney disease (CKD) and end-stage renal disease (ESRD). The primary therapeutic goals are to reduce proteinuria and slow disease progression.\n    -   **Immediate Step:** Initiate **Renin-Angiotensin-Aldosterone System (RAAS) blockade**, typically with an Angiotensin-Converting Enzyme (ACE) inhibitor or an Angiotensin II Receptor Blocker (ARB). These agents reduce proteinuria by decreasing efferent arteriolar tone, thereby lowering intraglomerular pressure, and also have antiproliferative and antifibrotic effects.\n    -   **Next Step for Immunosuppression:** Since corticosteroids have failed, a second-line immunosuppressive agent is required to attempt to induce remission. The standard of care for steroid-resistant FSGS is a **Calcineurin Inhibitor (CNI)**, such as tacrolimus or cyclosporine.\n    -   **Long-term:** The patient requires **close monitoring** of renal function, proteinuria, and blood pressure to manage the high risk of progression to CKD.\n\n### Option-by-Option Analysis\n\n**A. The $4$-year-old has Minimal Change Disease (MCD); EM shows diffuse podocyte foot process effacement without immune deposits; continue corticosteroids with gradual taper and supportive care. The $15$-year-old has Focal Segmental Glomerulosclerosis (FSGS); EM shows podocyte effacement with areas of segmental scarring; initiate Renin-Angiotensin-Aldosterone System (RAAS) blockade with an Angiotensin-Converting Enzyme (ACE) inhibitor and consider a Calcineurin Inhibitor (CNI) if nephrotic-range proteinuria persists, with close monitoring for progression to chronic kidney disease.**\n- This option correctly identifies the diagnosis (MCD), expected EM findings (podocyte effacement), and management (steroid taper) for Patient 1.\n- It also correctly identifies the diagnosis (FSGS), expected EM findings (effacement and scarring), and appropriate multi-pronged management strategy (RAAS blockade, consideration of CNI, monitoring) for Patient 2.\n- **Verdict: Correct.**\n\n**B. The $4$-year-old has Membranous Nephropathy; EM shows subepithelial immune complex deposits; initiate plasma exchange. The $15$-year-old has MCD; EM is normal; escalate corticosteroids indefinitely.**\n- Patient 1: The diagnosis of Membranous Nephropathy is inconsistent with the negative IF, rapid steroid response, and age.\n- Patient 2: The diagnosis of MCD is inconsistent with the steroid resistance and LM finding of segmental sclerosis. Escalating failed corticosteroids indefinitely is not appropriate management.\n- **Verdict: Incorrect.**\n\n**C. The $4$-year-old has FSGS due to apolipoprotein L1 (APOL1)-associated risk; EM shows segmental sclerosis and hyalinosis; initiate alkylating therapy with cyclophosphamide. The $15$-year-old has MCD; EM shows mesangial immunoglobulin A deposition; continue observation without RAAS blockade.**\n- Patient 1: The diagnosis of FSGS is incorrect; the clinical course and LM/IF findings are classic for MCD.\n- Patient 2: The diagnosis of MCD is incorrect. The finding of IgA deposition is for IgA nephropathy and contradicts the negative IF result in the problem statement.\n- **Verdict: Incorrect.**\n\n**D. The $4$-year-old has MCD; EM shows mesangial hypercellularity with subendothelial deposits; first-line treatment is mycophenolate mofetil. The $15$-year-old has FSGS; EM shows subendothelial immune complex deposits and low complement; treat with prolonged high-dose steroids alone despite resistance.**\n- Patient 1: The diagnosis of MCD is correct, but the described EM findings are for a different disease (e.g., MPGN Type I or lupus nephritis). Mycophenolate mofetil is not first-line therapy for an initial episode of MCD.\n- Patient 2: The diagnosis of FSGS is correct, but the described EM findings and low complement are inconsistent with the problem statement (negative IF, normal C3). Continuing steroids alone for resistant disease is improper management.\n- **Verdict: Incorrect.**",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}